Intravitreal dexamethasone implant for central retinal vein occlusion without macular edema

Eun Young Choi, Hyun Goo Kang, Sungchul Lee, Min Kim

Research output: Contribution to journalArticle

Abstract

Background: To evaluate the efficacy of an intravitreal dexamethasone (IVD) implant (Ozurdex®) for the treatment of central retinal vein occlusion (CRVO) without macular edema (ME). Methods: A retrospective cohort study was designed, and 20 eyes of 20 patients diagnosed with non-ischemic CRVO without ME were included. A total of 10 CRVO eyes were observed without treatment, and another 10 CRVO eyes received a single IVD injection at baseline. Mean changes in pathomorphologic parameters of fundus and optical coherence tomography parameters were measured at baseline and at 1, 3, 6, and 12 months. Results: The decreases in venous tortuosity (p = 0.014 for superior; 0.036 for inferior arcades) and width (p = 0.024 for superior; 0.003 for inferior arcades) from baseline to 12 months after injection were significantly greater in the treated group than the observed group. The improvements in RNFL swelling (p = 0.010) and retinal hemorrhage (p = 0.006) were also significantly greater in the treated group. Visual symptom improvement was significantly faster in the treated group (p = 0.001). In two cases, IVD injection resulted in complete resolution of cilioretinal artery occlusion associated with the CRVO, leading to complete visual recovery in 1 week. None of the treated eyes showed signs of ME development, ischemia progression, or neovascularization. Conclusions: IVD implant was significantly effective in improving venous engorgement, retinal hemorrhage, RNFL swelling, and visual symptoms by presumed alleviation of disc swelling and venous outflow. This treatment may be a considerable treatment option in CRVO patients with no ME.

Original languageEnglish
Article number92
JournalBMC Ophthalmology
Volume19
Issue number1
DOIs
Publication statusPublished - 2019 Apr 17

Fingerprint

Retinal Vein
Retinal Vein Occlusion
Macular Edema
Dexamethasone
Retinal Hemorrhage
Intravitreal Injections
Hyperemia
Optical Coherence Tomography
Therapeutics
Cohort Studies
Ischemia
Retrospective Studies
Arteries
Injections

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

@article{67f1ef5b3f0d48b88b7d3bcaa619ab44,
title = "Intravitreal dexamethasone implant for central retinal vein occlusion without macular edema",
abstract = "Background: To evaluate the efficacy of an intravitreal dexamethasone (IVD) implant (Ozurdex{\circledR}) for the treatment of central retinal vein occlusion (CRVO) without macular edema (ME). Methods: A retrospective cohort study was designed, and 20 eyes of 20 patients diagnosed with non-ischemic CRVO without ME were included. A total of 10 CRVO eyes were observed without treatment, and another 10 CRVO eyes received a single IVD injection at baseline. Mean changes in pathomorphologic parameters of fundus and optical coherence tomography parameters were measured at baseline and at 1, 3, 6, and 12 months. Results: The decreases in venous tortuosity (p = 0.014 for superior; 0.036 for inferior arcades) and width (p = 0.024 for superior; 0.003 for inferior arcades) from baseline to 12 months after injection were significantly greater in the treated group than the observed group. The improvements in RNFL swelling (p = 0.010) and retinal hemorrhage (p = 0.006) were also significantly greater in the treated group. Visual symptom improvement was significantly faster in the treated group (p = 0.001). In two cases, IVD injection resulted in complete resolution of cilioretinal artery occlusion associated with the CRVO, leading to complete visual recovery in 1 week. None of the treated eyes showed signs of ME development, ischemia progression, or neovascularization. Conclusions: IVD implant was significantly effective in improving venous engorgement, retinal hemorrhage, RNFL swelling, and visual symptoms by presumed alleviation of disc swelling and venous outflow. This treatment may be a considerable treatment option in CRVO patients with no ME.",
author = "Choi, {Eun Young} and Kang, {Hyun Goo} and Sungchul Lee and Min Kim",
year = "2019",
month = "4",
day = "17",
doi = "10.1186/s12886-019-1097-y",
language = "English",
volume = "19",
journal = "BMC Ophthalmology",
issn = "1471-2415",
publisher = "BioMed Central",
number = "1",

}

Intravitreal dexamethasone implant for central retinal vein occlusion without macular edema. / Choi, Eun Young; Kang, Hyun Goo; Lee, Sungchul; Kim, Min.

In: BMC Ophthalmology, Vol. 19, No. 1, 92, 17.04.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intravitreal dexamethasone implant for central retinal vein occlusion without macular edema

AU - Choi, Eun Young

AU - Kang, Hyun Goo

AU - Lee, Sungchul

AU - Kim, Min

PY - 2019/4/17

Y1 - 2019/4/17

N2 - Background: To evaluate the efficacy of an intravitreal dexamethasone (IVD) implant (Ozurdex®) for the treatment of central retinal vein occlusion (CRVO) without macular edema (ME). Methods: A retrospective cohort study was designed, and 20 eyes of 20 patients diagnosed with non-ischemic CRVO without ME were included. A total of 10 CRVO eyes were observed without treatment, and another 10 CRVO eyes received a single IVD injection at baseline. Mean changes in pathomorphologic parameters of fundus and optical coherence tomography parameters were measured at baseline and at 1, 3, 6, and 12 months. Results: The decreases in venous tortuosity (p = 0.014 for superior; 0.036 for inferior arcades) and width (p = 0.024 for superior; 0.003 for inferior arcades) from baseline to 12 months after injection were significantly greater in the treated group than the observed group. The improvements in RNFL swelling (p = 0.010) and retinal hemorrhage (p = 0.006) were also significantly greater in the treated group. Visual symptom improvement was significantly faster in the treated group (p = 0.001). In two cases, IVD injection resulted in complete resolution of cilioretinal artery occlusion associated with the CRVO, leading to complete visual recovery in 1 week. None of the treated eyes showed signs of ME development, ischemia progression, or neovascularization. Conclusions: IVD implant was significantly effective in improving venous engorgement, retinal hemorrhage, RNFL swelling, and visual symptoms by presumed alleviation of disc swelling and venous outflow. This treatment may be a considerable treatment option in CRVO patients with no ME.

AB - Background: To evaluate the efficacy of an intravitreal dexamethasone (IVD) implant (Ozurdex®) for the treatment of central retinal vein occlusion (CRVO) without macular edema (ME). Methods: A retrospective cohort study was designed, and 20 eyes of 20 patients diagnosed with non-ischemic CRVO without ME were included. A total of 10 CRVO eyes were observed without treatment, and another 10 CRVO eyes received a single IVD injection at baseline. Mean changes in pathomorphologic parameters of fundus and optical coherence tomography parameters were measured at baseline and at 1, 3, 6, and 12 months. Results: The decreases in venous tortuosity (p = 0.014 for superior; 0.036 for inferior arcades) and width (p = 0.024 for superior; 0.003 for inferior arcades) from baseline to 12 months after injection were significantly greater in the treated group than the observed group. The improvements in RNFL swelling (p = 0.010) and retinal hemorrhage (p = 0.006) were also significantly greater in the treated group. Visual symptom improvement was significantly faster in the treated group (p = 0.001). In two cases, IVD injection resulted in complete resolution of cilioretinal artery occlusion associated with the CRVO, leading to complete visual recovery in 1 week. None of the treated eyes showed signs of ME development, ischemia progression, or neovascularization. Conclusions: IVD implant was significantly effective in improving venous engorgement, retinal hemorrhage, RNFL swelling, and visual symptoms by presumed alleviation of disc swelling and venous outflow. This treatment may be a considerable treatment option in CRVO patients with no ME.

UR - http://www.scopus.com/inward/record.url?scp=85064481856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064481856&partnerID=8YFLogxK

U2 - 10.1186/s12886-019-1097-y

DO - 10.1186/s12886-019-1097-y

M3 - Article

VL - 19

JO - BMC Ophthalmology

JF - BMC Ophthalmology

SN - 1471-2415

IS - 1

M1 - 92

ER -